Most Active
Iovance Biotherapeutics Raises Full-Year 2026 Revenue Guidance to $410-$420 Million, Stock Surges 33%
Read this in the Market Flux appIovance Biotherapeutics, Inc. $IOVA
$14.45+31.48%as of publication
- 5D Change
- +35.81%
- Notional
- $1.08B
Iovance Biotherapeutics raised its full-year 2026 total revenue guidance range to $410 to $420 million, well above prior analyst estimates, citing strong U.S. demand for its melanoma cell therapy Amtagvi and Proleukin. The announcement, disclosed in an 8-K filing on September 29, sent shares surging as much as 33% during midday trading after climbing roughly 11% in premarket activity.
TD Cowen responded by raising its price target on the stock, reflecting confidence in the company's commercial trajectory. Analysts framed the guidance upgrade as a signal that Iovance has entered a new phase of growth, with domestic demand for its treatments running ahead of earlier projections.
© AI-generated summary is provided by Market Flux
Sources
- InvestingForm 8K Iovance Biotherapeutics Inc For: 29 September
- ZerohedgePremarket movers: Mag 7 stocks are mixed (Alphabet (GOOGL) -0.08%, Amazon (AMZN) +0.3%, Apple (AAPL) -0.4%, Meta Platforms (META) +0.8%, Microsoft (MSFT) -0.08%, Nvidia (NVDA) +0.6%, Tesla (TSLA) +0.3%) AAR (AIR) gains 5% after the aerospace and defense company reported adjusted diluted earnings per share and revenue for the first quarter that beat the average analyst estimate. Fair Issac (FICO), a credit score company, slumps 18% after Federal Housing Finance Agency Director Bill Pulte announced a move that makes it easier for lenders to adopt VantageScore. According to analysts, this will increase competition while pressuring Fair Issac’s market share and pricing power. FuelCell Energy (FCEL) rises 5% after Oppenheimer & Co initiated coverage of the fuel cell maker with a recommendation of outperform, expecting demand to stay “well ahead” of supply as it ramps up its production capacity. Iovance Biotherapeutics (IOVA) climbs 5% after boosting its revenue guidance for the full year. Ltd. (MNDY) slips 1.8% after JPMorgan downgraded the software company to neutral from overweight, citing growth challenges for annual recurring revenue. Netflix (NFLX) inches 1% higher after Deutsche Bank upgraded the streaming-video company to buy, saying that concerns about engagement were overblown. Summit Therapeutics (SMMT) rises 16% after AstraZeneca announced an investment in the biotech to collaborate on new cancer medication. Uniqure (QURE) slumps 58% after saying that the benefits of its Huntington’s disease gene therapy drug AMT-130 were not as good after four years as they were after three years in a small trial — a result that could complicate its bid to get the treatment approved by US regulators.
- OpenOutcrier$IOVA (+11.3% pre) Iovance Biotherapeutics (IOVA) Raises 2026 Revenue Forecast Above Analyst Estimates
- NasdaqIovance Biotherapeutics Stock Rises 33% After Raising FY26 Total Revenue Outlook
- CnbcStocks making the biggest moves midday: Carnival, Fair Isaac, Bloom Energy, Iovance Biotherapeutics & more